Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Clinical Trials: Overview01:11

Clinical Trials: Overview

3.4K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
3.4K
Drug Administration and Therapy Phases: Overview01:26

Drug Administration and Therapy Phases: Overview

738
Drugs, the chemical agents used in diagnosing, treating, or preventing diseases, undergo a four-phase process of development: pharmaceutic, pharmacokinetics, pharmacodynamics, and therapeutic.
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
738
Clinical Trials01:16

Clinical Trials

8.1K
Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
8.1K
Preclinical Development: Overview01:28

Preclinical Development: Overview

4.8K
Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
4.8K
Drug Discovery: Overview01:26

Drug Discovery: Overview

8.7K
Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...
8.7K
Dosage Regimen: Fixed Dose01:01

Dosage Regimen: Fixed Dose

2.0K
Fixed-dose regimens are a common approach to administer drugs to achieve and maintain desired levels of the drug in the body. In this dosing strategy, a specific amount of medication is given at regular intervals, often multiple times a day, to ensure a consistent drug concentration in the bloodstream.
Fixed-dose regimens can be used for various routes of administration, including intravenous (IV) injections and oral medications. For IV administration, a predetermined amount of the drug is...
2.0K

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Designing Zn-doped nickel sulfide catalysts with an optimized electronic structure for enhanced hydrogen evolution reaction.

Nanoscale·2021
Same author

Clinical characteristics of low-grade tumor-related epilepsy and its predictors for surgical outcome.

Annals of clinical and translational neurology·2021
Same author

Switching Spinless and Spinful Topological Phases with Projective PT Symmetry.

Physical review letters·2021
Same author

Comparison of Duration of Response vs Conventional Response Rates and Progression-Free Survival as Efficacy End Points in Simulated Immuno-oncology Clinical Trials.

JAMA network open·2021
Same author

Polyphyllin Ⅲ-Induced Ferroptosis in MDA-MB-231 Triple-Negative Breast Cancer Cells can Be Protected Against by KLF4-Mediated Upregulation of xCT.

Frontiers in pharmacology·2021
Same author

Independent action models and prediction of combination treatment effects for response rate, duration of response and tumor size change in oncology drug development.

Contemporary clinical trials·2021
Same journal

Are older adult research participants representative of the general population? Results from 19 clinical studies at one academic research center.

Contemporary clinical trials·2026
Same journal

Multi-site feasibility of a web-based and telephone navigation intervention to connect lung cancer caregivers in community oncology settings with resources: Protocol for the WF-2301CD caregiver oncology needs evaluation tool (CONNECT) trial.

Contemporary clinical trials·2026
Same journal

Rationale and design of a CArdiac rehabilitation program on the prevention of CardioTOXicity in breast Cancer patients undergoing treatment with anthracyclines and/or trastuzumab (CARPTOX-BC) trial: A randomized, active control group, open-label trial.

Contemporary clinical trials·2026
Same journal

Evaluating clinical outcomes of using Undermyfork mobile app with Dexcom G7: Protocol for CGM-Undermyfork randomized controlled trial.

Contemporary clinical trials·2026
Same journal

Outcomes of dyadic recruitment in the promoting re-engagement in meaningful activity (PRIMA) trial.

Contemporary clinical trials·2026
Same journal

Overview of the linking exercise for advancing daily stress (LEADS) management and resilience randomized controlled trial in African American families.

Contemporary clinical trials·2026
查看所有相关文章

相关实验视频

Updated: Sep 10, 2025

Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies
08:34

Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies

Published on: February 6, 2019

20.5K

适应性2/3阶段设计与剂量优化.

Cong Chen1, Mo Huang1, Xuekui Zhang2

  • 1Biostatistics and Research Decision Sciences, Merck & Co., Inc., Rahway, NJ 07065, USA.

Contemporary clinical trials
|August 19, 2025
PubMed
概括
此摘要是机器生成的。

美国食品药品监督管理局 FDA FDA

关键词:
组合测试试验 组合测试试验早期的终点是早期的终点.总体生存率 总体生存率项目的终点项目终点.

更多相关视频

Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction
09:44

Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction

Published on: January 29, 2019

10.2K
Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure
09:38

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Published on: August 11, 2017

8.9K

相关实验视频

Last Updated: Sep 10, 2025

Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies
08:34

Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies

Published on: February 6, 2019

20.5K
Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction
09:44

Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction

Published on: January 29, 2019

10.2K
Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure
09:38

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Published on: August 11, 2017

8.9K

科学领域:

  • 瘤学 药物开发 药物开发
  • 生物统计学 生物统计学
  • 临床试验设计 临床试验设计

背景情况:

  • 美国食品和药物管理局的Project Optimus旨在优化瘤药物剂量,以提高疗效和安全性.
  • 适应性2/3期设计用于剂量选择,通常采用反向正常组合测试来控制I型错误.
  • 过于保守的测试会导致I型错误,增加样本大小和延迟时间表,这阻碍了Project Optimus的采用.

研究的目的:

  • 解决适应性瘤学试验设计中的I型错误膨胀问题.
  • 调查早期剂量选择对长期疗效和安全结果的影响.
  • 建议在符合 Project Optimus 的试验中改进剂量选择方法.

主要方法:

  • 讨论根据中间数据选择次优剂量的概率的估计.
  • 在现实的临床试验环境中分析这种概率对I型错误率的影响.
  • 开发和整合两个新的方法,明确考虑这种概率.

主要成果:

  • 传统的逆正常组合测试可以导致显著的I型错误膨胀.
  • 与传统方法相比,提出的方法证明了I型错误控制的改进.
  • 准确估计亚最佳剂量选择的概率对于可靠的试验设计至关重要.

结论:

  • 拟议的方法在适应性瘤学试验中提供了增强的I型错误控制.
  • 这些改进的设计可以减轻样本大小的增加和时间表延迟.
  • 采用这些方法可能会鼓励人们更加坚持FDA的Project Optimus倡议,从而彻底改变瘤学药物开发.